- In February 2025, Mitsubishi Tanabe Pharma launched a new topical therapy for localized scleroderma in Japan, targeting pediatric patients.
- In January 2025, Roche expanded its Actemra (tocilizumab) scleroderma study to India and Indonesia as part of its APAC rare disease strategy.
- In October 2024, a multicenter trial evaluating sildenafil for digital ulcers in systemic sclerosis was launched across 5 Chinese hospitals.
- In March 2025, Pfizer Inc. partnered with the Japan Scleroderma Research Network (JSRN) to launch a post-marketing surveillance program evaluating long-term outcomes of immunosuppressants in systemic sclerosis patients, marking a strategic step towards real-world data collection and label expansion in the Japanese market.
- In April 2025, Roche initiated a multicenter Phase II clinical trial in Australia, Singapore, and South Korea for a novel antifibrotic monoclonal antibody targeting skin and lung fibrosis in systemic sclerosis, aiming to address unmet needs in severe scleroderma manifestations through precision biologics.
